Skip header and navigation

Refine By

2858 records – page 1 of 286.

1st European Congress on Parenteral and Enteral Nutrition. Stockholm, Sweden. September 2--5, 1979.

https://arctichealth.org/en/permalink/ahliterature62440
Source
JPEN J Parenter Enteral Nutr. 1979 Jul-Aug;3(4):289-316
Publication Type
Conference/Meeting Material
Source
JPEN J Parenter Enteral Nutr. 1979 Jul-Aug;3(4):289-316
Language
English
Publication Type
Conference/Meeting Material
Keywords
Congresses
Enteral Nutrition
Europe
Humans
Metabolism
Nutrition
Parenteral Nutrition
Sweden
PubMed ID
39184 View in PubMed
Less detail

2nd-generation HIV surveillance and injecting drug use: uncovering the epidemiological ice-berg.

https://arctichealth.org/en/permalink/ahliterature84543
Source
Int J Public Health. 2007;52(3):166-72
Publication Type
Article
Date
2007
Author
Reintjes Ralf
Wiessing Lucas
Author Affiliation
Department of Public Health, Faculty Life Sciences, Hamburg University of Applied Sciences, Hamburg, Germany. Ralf.Reintjes@rzbd.haw-hamburg.de
Source
Int J Public Health. 2007;52(3):166-72
Date
2007
Language
English
Publication Type
Article
Keywords
Acquired Immunodeficiency Syndrome - epidemiology - prevention & control - therapy
Cost-Benefit Analysis
Europe - epidemiology
HIV Infections - epidemiology - prevention & control - therapy
Hepatitis C - epidemiology
Humans
Norway - epidemiology
Population Surveillance
Prevalence
Risk factors
Risk-Taking
Substance Abuse, Intravenous - epidemiology
Turkey - epidemiology
Abstract
OBJECTIVES: HIV/AIDS surveillance methods are under revision as the diversity of HIV epidemics is becoming more apparent. The so called "2nd generation surveillance (SGS) systems" aim to enhance surveillance by broadening the range of indicators to prevalence, behaviors and correlates, for a better understanding and a more complete and timely awareness of evolving epidemics. METHODS: Concepts of HIV SGS are reviewed with a special focus on injecting drug users, a major at-risk and hard to reach group in Europe, a region with mainly low or concentrated epidemics. RESULTS: The scope of HIV/AIDS surveillance needs to be broadened following principles of SGS. Specifically for IDUs we propose including hepatitis C data as indicator for injecting risk in routine systems like those monitoring sexually transmitted infections and information on knowledge and attitudes as potential major determinants of risk behavior. CONCLUSIONS: The suggested approach should lead to more complete and timely information for public health interventions, however there is a clear need for comparative validation studies to assess the validity, reliability and cost-effectiveness of traditional and enhanced HIV/AIDS surveillance systems.
PubMed ID
17958283 View in PubMed
Less detail

4th European Public Health Conference 2011 in Copenhagen: Public Health and Welfare--Welfare Development and Health .

https://arctichealth.org/en/permalink/ahliterature137620
Source
Scand J Public Health. 2011 Feb;39(1):1-2
Publication Type
Article
Date
Feb-2011
Author
Finn Kamper-Jørgensen
Source
Scand J Public Health. 2011 Feb;39(1):1-2
Date
Feb-2011
Language
English
Publication Type
Article
Keywords
Denmark
Europe
Health promotion
Humans
Public Health
World Health
PubMed ID
21266586 View in PubMed
Less detail

The 6-F nitinol TrapEase inferior vena cava filter: results of a prospective multicenter trial.

https://arctichealth.org/en/permalink/ahliterature195125
Source
J Vasc Interv Radiol. 2001 Mar;12(3):299-304
Publication Type
Article
Date
Mar-2001
Author
H. Rousseau
P. Perreault
P. Otal
L. Stockx
J. Golzarian
V. Oliva
P. Reynaud
F. Raat
F. Szatmari
G. Santoro
G. Emanuelli
M. Nonent
Y. Hoogeveen
Author Affiliation
Radiology Department, CHU Rangueil, Toulouse, France. rousseau.h@chu-toulouse.fr
Source
J Vasc Interv Radiol. 2001 Mar;12(3):299-304
Date
Mar-2001
Language
English
Publication Type
Article
Keywords
Aged
Alloys
Canada
Equipment Design
Europe
Female
Follow-Up Studies
Humans
Male
Prospective Studies
Pulmonary Embolism - prevention & control
Risk
Time Factors
Vena Cava Filters - adverse effects
Venous Thrombosis - epidemiology
Abstract
The authors report the first results of a new 6-F symmetrically designed permanent nitinol inferior vena cava (IVC) filter, the Cordis TrapEase, evaluated in a multicenter prospective study with 6-months of follow-up.
A total of 65 patients (29 men, 36 women) who ranged in age from 37 to 96 years (mean age, 68 years) and who were at high risk of pulmonary embolism (PE) were enrolled in 12 centers in Europe and Canada. The study was approved by the institutional review boards at all centers. Study objectives were to evaluate filter effectiveness, filter stability, and caval occlusion. Indications for filter placement were deep vein thrombosis with recurrent thromboembolism and/or free-floating thrombus with contraindication to anticoagulation in 37 patients, and complications in achieving adequate anticoagulation in 28 patients. Follow-up included clinical examination, plain film, Doppler ultrasound, CT scan, and nuclear medicine.
The analysis of the data revealed a technical success of 95.4% (three filter-system related implantations not at the intended site, no events of filter tilting) and a clinical success of 100% at 6 months (no cases of symptomatic PE), the study primary endpoint. There were no cases (0%) of filter migration, insertion site thrombosis, filter fracture, or vessel wall perforation. During the study period, there were two cases of filter thrombosis: one case of early symptomatic thrombosis that was successfully treated in the hospital, and one case of nonsymptomatic filter thrombosis detected at 1-month follow-up, with spontaneous recanalization at 3 months. In the latter patient, some residual thrombus was still detected at 6 months. Of the study population of 65 patients, there were 23 deaths. These deaths were not related to the device or the implantation procedure but to the underlying disease process.
This study demonstrates the new nitinol permanent IVC filter to be a safe and an effective device, with a low overall complication rate, for use in patients with thromboembolic disease at high risk of PE.
PubMed ID
11287505 View in PubMed
Less detail

The 6th Klaas Breur memorial lecture, 1987. The Chernobyl accident--impact Western Europe.

https://arctichealth.org/en/permalink/ahliterature25858
Source
Radiother Oncol. 1988 May;12(1):1-13
Publication Type
Article
Date
May-1988

The 7th European Placenta Group Meeting, Vigsø, Denmark, 13-17 December 1997.

https://arctichealth.org/en/permalink/ahliterature64188
Source
Placenta. 1998 May;19(4):341-4
Publication Type
Conference/Meeting Material
Date
May-1998
Author
C H Graham
Author Affiliation
Department of Anatomy and Cell Biology, Queen's University, Kingston, Ontario, Canada.
Source
Placenta. 1998 May;19(4):341-4
Date
May-1998
Language
English
Publication Type
Conference/Meeting Material
Keywords
Animals
Disease Transmission, Vertical
Drug Delivery Systems
Europe
Female
Humans
Maternal-Fetal Exchange
Pharmacokinetics
Placenta - physiology
Pregnancy
PubMed ID
9735019 View in PubMed
Less detail

A 15-month evaluation of the effects of repeated subgingival minocycline in chronic adult periodontitis.

https://arctichealth.org/en/permalink/ahliterature201582
Source
J Periodontol. 1999 Jun;70(6):657-67
Publication Type
Article
Date
Jun-1999
Author
D. van Steenberghe
B. Rosling
P O Söder
R G Landry
U. van der Velden
M F Timmerman
E F McCarthy
G. Vandenhoven
C. Wouters
M. Wilson
J. Matthews
H N Newman
Author Affiliation
Catholic University, Leuven, Belgium.
Source
J Periodontol. 1999 Jun;70(6):657-67
Date
Jun-1999
Language
English
Publication Type
Article
Keywords
Adult
Aggregatibacter actinomycetemcomitans - drug effects
Analysis of Variance
Anti-Bacterial Agents - administration & dosage
Campylobacter - drug effects
Canada
Chronic Disease
Colony Count, Microbial
Dental Plaque Index
Dental Scaling
Double-Blind Method
Eikenella corrodens - drug effects
Europe
Female
Fusobacterium nucleatum - drug effects
Humans
Longitudinal Studies
Male
Middle Aged
Minocycline - administration & dosage
Ointments
Periodontal Index
Periodontal Pocket - drug therapy - microbiology
Periodontitis - drug therapy - microbiology
Porphyromonas gingivalis - drug effects
Prevotella intermedia - drug effects
Statistics, nonparametric
Treatment Outcome
Treponema - drug effects
Abstract
A double-blind, randomized, parallel, comparative study was designed to evaluate the long-term safety and efficacy of subgingivally administered minocycline ointment versus a vehicle control.
One hundred four patients (104) with moderate to severe adult periodontitis (34 to 64 years of age; mean 46 years) were enrolled in the study. Following scaling and root planing, patients were randomized to receive either 2% minocycline ointment or a matched vehicle control. Study medication was administered directly into the periodontal pocket with a specially designed, graduated, disposable applicator at baseline; week 2; and at months 1, 3, 6, 9, and 12. Scaling and root planing was repeated at months 6 and 12. Standard clinical variables (including probing depth and attachment level) were evaluated at baseline and at months 1, 3, 6, 9, 12, and 15. Microbiological sampling using DNA probes was done at baseline; at week 2; and at months 1, 3, 6, 9, 12, and 15.
Both treatment groups showed significant and clinically relevant reductions in the numbers of each of the 7 microorganisms measured during the entire 15-month study period. When differences were detected, sites treated with minocycline ointment always produced statistically significantly greater reductions than sites which received the vehicle control. For initial pockets > or =5 mm, a mean reduction in probing depth of 1.9 mm was seen in the test sites, versus 1.2 mm in the control sites. Sites with a baseline probing depth > or =7 mm and bleeding index >2 showed an average of 2.5 mm reduction with minocycline versus 1.5 mm with the vehicle. Gains in attachment (0.9 mm and 1.1 mm) were observed in minocycline-treated sites, with baseline probing depth > or =5 mm and > or =7 mm, respectively, compared with 0.5 mm and 0.7 mm gain at control sites. Subgingival administration of minocycline ointment was well tolerated.
Overall, the results demonstrate that repeated subgingival administration of minocycline ointment in the treatment of adult periodontitis is safe and leads to significant adjunctive improvement after subgingival instrumentation in both clinical and microbiologic variables over a 15-month period.
PubMed ID
10397521 View in PubMed
Less detail

24th European Academy of Dermatology and Venereology.

https://arctichealth.org/en/permalink/ahliterature278271
Source
Immunotherapy. 2016;8(4):395-7
Publication Type
Conference/Meeting Material
Date
2016
Author
Anja C Rasch
Source
Immunotherapy. 2016;8(4):395-7
Date
2016
Language
English
Publication Type
Conference/Meeting Material
Keywords
Animals
Denmark
Dermatologists
Dermatology - trends
Europe
Humans
Skin Diseases - immunology
Societies, Scientific
Venereology - trends
Abstract
The 24th European Academy of Dermatology and Venereology was held in Copenhagen, Denmark, from 7-11 October 2015. It has become Europe's biggest meeting of its kind with roughly 10,000 participants, approximately 3000 abstracts and about 180 exhibitors from all over the world. The organizers offer a venue for the latest cutting edge research and newest developments. Thus, their goal is to foster progress in clinical care and promote scientific excellence related to dermatovenereology for the benefit of patients with skin diseases.
PubMed ID
26973121 View in PubMed
Less detail

99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: immune therapies of type 1 diabetes: new opportunities based on the hygiene hypothesis.

https://arctichealth.org/en/permalink/ahliterature144028
Source
Clin Exp Immunol. 2010 Apr;160(1):106-12
Publication Type
Article
Date
Apr-2010
Author
L. Chatenoud
S. You
H. Okada
C. Kuhn
B. Michaud
J-F Bach
Author Affiliation
Université Paris Descarte, Paris, France. lucienne.chatenoud@inserm.fr
Source
Clin Exp Immunol. 2010 Apr;160(1):106-12
Date
Apr-2010
Language
English
Publication Type
Article
Keywords
Adolescent
Animals
Autoantigens - immunology
Bacteria - immunology
Canada - epidemiology
Child
Diabetes Mellitus, Type 1 - immunology - therapy
Europe - epidemiology
Humans
Hygiene
Hypersensitivity - immunology
Immunosuppression - methods
Immunotherapy - methods
Infection - immunology - microbiology
Mice
Pancreatitis - immunology - microbiology
Toll-Like Receptors - agonists
Young Adult
Abstract
Insulin-dependent (type 1) diabetes is a prototypic organ-specific autoimmune disease resulting from the selective destruction of insulin-secreting beta cells within pancreatic islets of Langerhans by an immune-mediated inflammation involving autoreactive CD4(+) and CD8(+) T lymphocytes which infiltrate pancreatic islets. Current treatment is substitutive, i.e. chronic use of exogenous insulin which, in spite of significant advances, is still associated with major constraints (multiple daily injections, risks of hypoglycaemia) and lack of effectiveness over the long term in preventing severe degenerative complications. Finding a cure for autoimmune diabetes by establishing effective immune-based therapies is a real medical health challenge, as the disease incidence increases steadily in industrialized countries. As the disease affects mainly children and young adults, any candidate immune therapy must therefore be safe and avoid a sustained depression of immune responses with the attendant problems of recurrent infection and drug toxicity. Thus, inducing or restoring immune tolerance to target autoantigens, controlling the pathogenic response while preserving the host reactivity to exogenous/unrelated antigens, appears to be the ideal approach. Our objective is to review the major progress accomplished over the last 20 years towards that aim. In addition, we would like to present another interesting possibility to access new preventive strategies based on the 'hygiene hypothesis', which proposes a causal link between the increasing incidence of autoimmune diseases, including diabetes, and the decrease of the infectious burden. The underlying rationale is to identify microbial-derived compounds mediating the protective activity of infections which could be developed therapeutically.
Notes
Cites: J Immunol. 2000 Jun 1;164(11):5683-810820244
Cites: Clin Exp Immunol. 2010 Apr;160(1):1-920415844
Cites: Lancet. 2000 Aug 12;356(9229):545-910950231
Cites: Diabetologia. 2000 Aug;43(8):1000-410990077
Cites: J Immunol. 2000 Dec 1;165(11):6148-5511086048
Cites: Annu Rev Immunol. 2001;19:131-6111244033
Cites: J Immunol. 2001 Jul 15;167(2):1081-911441119
Cites: Lancet. 2001 Nov 24;358(9295):1749-5311734230
Cites: Nature. 2002 Apr 11;416(6881):603-711948342
Cites: Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5539-4411943868
Cites: N Engl J Med. 2002 May 30;346(22):1685-9112037147
Cites: N Engl J Med. 2002 May 30;346(22):1740-212037155
Cites: N Engl J Med. 2002 Sep 19;347(12):911-2012239261
Cites: Vaccine. 2003 Feb 14;21(9-10):836-4212547591
Cites: Int Immunopharmacol. 2003 Mar;3(3):417-2512639819
Cites: Science. 1984 Mar 30;223(4643):1362-76367043
Cites: Lancet. 1986 Jul 19;2(8499):119-242873396
Cites: Diabetes. 1986 Aug;35(8):855-603525284
Cites: J Exp Med. 1989 May 1;169(5):1669-802523954
Cites: BMJ. 1989 Nov 18;299(6710):1259-602513902
Cites: J Autoimmun. 1989 Dec;2(6):759-762533502
Cites: Chem Pharm Bull (Tokyo). 1992 Apr;40(4):1004-61525928
Cites: Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):123-78278351
Cites: Endocr Rev. 1994 Aug;15(4):516-427988484
Cites: Diabetes Metab. 1996 Oct;22(5):341-88896996
Cites: J Exp Med. 1996 Nov 1;184(5):2049-538920894
Cites: J Immunol. 1997 Mar 15;158(6):2947-549058834
Cites: Immunology. 1962 May;5:378-8813887798
Cites: Nat Med. 2005 Feb;11(2):138-4515654326
Cites: N Engl J Med. 2005 Jun 23;352(25):2598-60815972866
Cites: J Exp Med. 2005 Oct 17;202(8):1131-916230478
Cites: J Exp Med. 2005 Nov 7;202(9):1171-716260486
Cites: Diabetes. 2006 Jan;55(1):179-8516380491
Cites: J Neuroimmunol. 2006 Mar;172(1-2):94-10316360885
Cites: Immunol Rev. 2006 Aug;212:185-20216903915
Cites: J Med Chem. 2006 Oct 5;49(20):6000-1417004714
Cites: Immunobiology. 2006;211(10):767-7717113914
Cites: Nat Rev Immunol. 2007 May;7(5):353-6417457343
Cites: Pediatr Diabetes. 2007 Oct;8 Suppl 6:6-1417727380
Cites: J Clin Invest. 2007 Dec;117(12):3857-6718060033
Cites: N Engl J Med. 2008 Feb 14;358(7):676-8818272891
Cites: J Immunol. 2008 Mar 1;180(5):2863-7518292508
Cites: Lancet. 2008 May 24;371(9626):1777-8218502302
Cites: N Engl J Med. 2008 Oct 30;359(18):1909-2018843118
Cites: Lancet. 2008 Nov 15;372(9651):1746-5518814906
Cites: Nat Rev Endocrinol. 2009 Apr;5(4):219-2619352320
Cites: Lancet. 2009 Jun 13;373(9680):2027-3319481249
Cites: Diabetes Care. 2009 Nov;32(11):2036-4019690081
Cites: N Engl J Med. 2009 Nov 26;361(22):2143-5219940299
Cites: Eur J Biochem. 2000 Jun;267(11):3370-710824125
PubMed ID
20415859 View in PubMed
Less detail

2858 records – page 1 of 286.